Medicenna Therapeutics Corp.
Medicenna Therapeutics Corp. (MDNA.TO) Stock Competitors & Peer Comparison
See (MDNA.TO) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| MDNA.TO | CA$0.64 | +4.92% | 44M | -4.27 | -CA$0.15 | N/A |
| BLU.TO | CA$19.48 | -0.10% | 2.5B | -20.29 | -CA$0.96 | N/A |
| MMED.NE | CA$14.90 | +9.48% | 1.1B | -4.50 | -CA$3.31 | N/A |
| DRUG.CN | CA$98.07 | +2.79% | 786.8M | -36.73 | -CA$2.76 | N/A |
| EPRX.TO | CA$10.33 | +11.08% | 360.8M | -7.02 | -CA$1.43 | N/A |
| FRX.TO | CA$8.33 | +0.00% | 236.4M | -17.23 | -CA$0.48 | N/A |
| CYBN.NE | CA$6.94 | +14.71% | 162.2M | -1.30 | -CA$5.17 | N/A |
| ONC.TO | CA$1.42 | +2.16% | 142.3M | -3.84 | -CA$0.37 | N/A |
| HBP.TO | CA$1.85 | -4.64% | 142.1M | -31.00 | -CA$0.06 | N/A |
| MSCL.TO | CA$8.44 | +0.48% | 124M | 2.26 | CA$3.55 | N/A |
Stock Comparison
MDNA.TO vs BLU.TO Comparison April 2026
MDNA.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDNA.TO stands at 44M. In comparison, BLU.TO has a market cap of 2.5B. Regarding current trading prices, MDNA.TO is priced at CA$0.64, while BLU.TO trades at CA$19.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDNA.TO currently has a P/E ratio of -4.27, whereas BLU.TO's P/E ratio is -20.29. In terms of profitability, MDNA.TO's ROE is -1.04%, compared to BLU.TO's ROE of -0.22%. Regarding short-term risk, MDNA.TO is less volatile compared to BLU.TO. This indicates potentially lower risk in terms of short-term price fluctuations for MDNA.TO.Check BLU.TO's competition here
MDNA.TO vs MMED.NE Comparison April 2026
MDNA.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDNA.TO stands at 44M. In comparison, MMED.NE has a market cap of 1.1B. Regarding current trading prices, MDNA.TO is priced at CA$0.64, while MMED.NE trades at CA$14.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDNA.TO currently has a P/E ratio of -4.27, whereas MMED.NE's P/E ratio is -4.50. In terms of profitability, MDNA.TO's ROE is -1.04%, compared to MMED.NE's ROE of -0.50%. Regarding short-term risk, MDNA.TO is less volatile compared to MMED.NE. This indicates potentially lower risk in terms of short-term price fluctuations for MDNA.TO.Check MMED.NE's competition here
MDNA.TO vs DRUG.CN Comparison April 2026
MDNA.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDNA.TO stands at 44M. In comparison, DRUG.CN has a market cap of 786.8M. Regarding current trading prices, MDNA.TO is priced at CA$0.64, while DRUG.CN trades at CA$98.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDNA.TO currently has a P/E ratio of -4.27, whereas DRUG.CN's P/E ratio is -36.73. In terms of profitability, MDNA.TO's ROE is -1.04%, compared to DRUG.CN's ROE of -0.28%. Regarding short-term risk, MDNA.TO is more volatile compared to DRUG.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MDNA.TO.Check DRUG.CN's competition here
MDNA.TO vs EPRX.TO Comparison April 2026
MDNA.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDNA.TO stands at 44M. In comparison, EPRX.TO has a market cap of 360.8M. Regarding current trading prices, MDNA.TO is priced at CA$0.64, while EPRX.TO trades at CA$10.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDNA.TO currently has a P/E ratio of -4.27, whereas EPRX.TO's P/E ratio is -7.02. In terms of profitability, MDNA.TO's ROE is -1.04%, compared to EPRX.TO's ROE of -0.66%. Regarding short-term risk, MDNA.TO is less volatile compared to EPRX.TO. This indicates potentially lower risk in terms of short-term price fluctuations for MDNA.TO.Check EPRX.TO's competition here
MDNA.TO vs FRX.TO Comparison April 2026
MDNA.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDNA.TO stands at 44M. In comparison, FRX.TO has a market cap of 236.4M. Regarding current trading prices, MDNA.TO is priced at CA$0.64, while FRX.TO trades at CA$8.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDNA.TO currently has a P/E ratio of -4.27, whereas FRX.TO's P/E ratio is -17.23. In terms of profitability, MDNA.TO's ROE is -1.04%, compared to FRX.TO's ROE of -2.36%. Regarding short-term risk, MDNA.TO is more volatile compared to FRX.TO. This indicates potentially higher risk in terms of short-term price fluctuations for MDNA.TO.Check FRX.TO's competition here
MDNA.TO vs CYBN.NE Comparison April 2026
MDNA.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDNA.TO stands at 44M. In comparison, CYBN.NE has a market cap of 162.2M. Regarding current trading prices, MDNA.TO is priced at CA$0.64, while CYBN.NE trades at CA$6.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDNA.TO currently has a P/E ratio of -4.27, whereas CYBN.NE's P/E ratio is -1.30. In terms of profitability, MDNA.TO's ROE is -1.04%, compared to CYBN.NE's ROE of -0.61%. Regarding short-term risk, MDNA.TO is less volatile compared to CYBN.NE. This indicates potentially lower risk in terms of short-term price fluctuations for MDNA.TO.Check CYBN.NE's competition here
MDNA.TO vs ONC.TO Comparison April 2026
MDNA.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDNA.TO stands at 44M. In comparison, ONC.TO has a market cap of 142.3M. Regarding current trading prices, MDNA.TO is priced at CA$0.64, while ONC.TO trades at CA$1.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDNA.TO currently has a P/E ratio of -4.27, whereas ONC.TO's P/E ratio is -3.84. In terms of profitability, MDNA.TO's ROE is -1.04%, compared to ONC.TO's ROE of -4.40%. Regarding short-term risk, MDNA.TO is less volatile compared to ONC.TO. This indicates potentially lower risk in terms of short-term price fluctuations for MDNA.TO.Check ONC.TO's competition here
MDNA.TO vs HBP.TO Comparison April 2026
MDNA.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDNA.TO stands at 44M. In comparison, HBP.TO has a market cap of 142.1M. Regarding current trading prices, MDNA.TO is priced at CA$0.64, while HBP.TO trades at CA$1.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDNA.TO currently has a P/E ratio of -4.27, whereas HBP.TO's P/E ratio is -31.00. In terms of profitability, MDNA.TO's ROE is -1.04%, compared to HBP.TO's ROE of -0.37%. Regarding short-term risk, MDNA.TO is less volatile compared to HBP.TO. This indicates potentially lower risk in terms of short-term price fluctuations for MDNA.TO.Check HBP.TO's competition here
MDNA.TO vs MSCL.TO Comparison April 2026
MDNA.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDNA.TO stands at 44M. In comparison, MSCL.TO has a market cap of 124M. Regarding current trading prices, MDNA.TO is priced at CA$0.64, while MSCL.TO trades at CA$8.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDNA.TO currently has a P/E ratio of -4.27, whereas MSCL.TO's P/E ratio is 2.26. In terms of profitability, MDNA.TO's ROE is -1.04%, compared to MSCL.TO's ROE of -0.73%. Regarding short-term risk, MDNA.TO is less volatile compared to MSCL.TO. This indicates potentially lower risk in terms of short-term price fluctuations for MDNA.TO.Check MSCL.TO's competition here
MDNA.TO vs MSET.CN Comparison April 2026
MDNA.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDNA.TO stands at 44M. In comparison, MSET.CN has a market cap of 75M. Regarding current trading prices, MDNA.TO is priced at CA$0.64, while MSET.CN trades at CA$0.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDNA.TO currently has a P/E ratio of -4.27, whereas MSET.CN's P/E ratio is -12.33. In terms of profitability, MDNA.TO's ROE is -1.04%, compared to MSET.CN's ROE of -3.16%. Regarding short-term risk, Volatility data is not available for a full comparison. MDNA.TO has daily volatility of 1.55 and MSET.CN has daily volatility of N/A.Check MSET.CN's competition here
MDNA.TO vs SVA.TO Comparison April 2026
MDNA.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDNA.TO stands at 44M. In comparison, SVA.TO has a market cap of 52.2M. Regarding current trading prices, MDNA.TO is priced at CA$0.64, while SVA.TO trades at CA$0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDNA.TO currently has a P/E ratio of -4.27, whereas SVA.TO's P/E ratio is -3.75. In terms of profitability, MDNA.TO's ROE is -1.04%, compared to SVA.TO's ROE of +0.52%. Regarding short-term risk, MDNA.TO is less volatile compared to SVA.TO. This indicates potentially lower risk in terms of short-term price fluctuations for MDNA.TO.Check SVA.TO's competition here
MDNA.TO vs PMN.TO Comparison April 2026
MDNA.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDNA.TO stands at 44M. In comparison, PMN.TO has a market cap of 51.5M. Regarding current trading prices, MDNA.TO is priced at CA$0.64, while PMN.TO trades at CA$6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDNA.TO currently has a P/E ratio of -4.27, whereas PMN.TO's P/E ratio is -1.78. In terms of profitability, MDNA.TO's ROE is -1.04%, compared to PMN.TO's ROE of -5.57%. Regarding short-term risk, MDNA.TO is less volatile compared to PMN.TO. This indicates potentially lower risk in terms of short-term price fluctuations for MDNA.TO.Check PMN.TO's competition here
MDNA.TO vs IGX.TO Comparison April 2026
MDNA.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDNA.TO stands at 44M. In comparison, IGX.TO has a market cap of 41.9M. Regarding current trading prices, MDNA.TO is priced at CA$0.64, while IGX.TO trades at CA$0.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDNA.TO currently has a P/E ratio of -4.27, whereas IGX.TO's P/E ratio is -3.00. In terms of profitability, MDNA.TO's ROE is -1.04%, compared to IGX.TO's ROE of +1.27%. Regarding short-term risk, MDNA.TO is less volatile compared to IGX.TO. This indicates potentially lower risk in terms of short-term price fluctuations for MDNA.TO.Check IGX.TO's competition here
MDNA.TO vs MBX.TO Comparison April 2026
MDNA.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDNA.TO stands at 44M. In comparison, MBX.TO has a market cap of 31.9M. Regarding current trading prices, MDNA.TO is priced at CA$0.64, while MBX.TO trades at CA$0.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDNA.TO currently has a P/E ratio of -4.27, whereas MBX.TO's P/E ratio is -7.67. In terms of profitability, MDNA.TO's ROE is -1.04%, compared to MBX.TO's ROE of -0.15%. Regarding short-term risk, MDNA.TO is more volatile compared to MBX.TO. This indicates potentially higher risk in terms of short-term price fluctuations for MDNA.TO.Check MBX.TO's competition here
MDNA.TO vs DTC.CN Comparison April 2026
MDNA.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDNA.TO stands at 44M. In comparison, DTC.CN has a market cap of 31.6M. Regarding current trading prices, MDNA.TO is priced at CA$0.64, while DTC.CN trades at CA$0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDNA.TO currently has a P/E ratio of -4.27, whereas DTC.CN's P/E ratio is -6.87. In terms of profitability, MDNA.TO's ROE is -1.04%, compared to DTC.CN's ROE of +4.22%. Regarding short-term risk, MDNA.TO is less volatile compared to DTC.CN. This indicates potentially lower risk in terms of short-term price fluctuations for MDNA.TO.Check DTC.CN's competition here
MDNA.TO vs RVX.TO Comparison April 2026
MDNA.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDNA.TO stands at 44M. In comparison, RVX.TO has a market cap of 30.2M. Regarding current trading prices, MDNA.TO is priced at CA$0.64, while RVX.TO trades at CA$0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDNA.TO currently has a P/E ratio of -4.27, whereas RVX.TO's P/E ratio is -2.62. In terms of profitability, MDNA.TO's ROE is -1.04%, compared to RVX.TO's ROE of +0.08%. Regarding short-term risk, MDNA.TO is more volatile compared to RVX.TO. This indicates potentially higher risk in terms of short-term price fluctuations for MDNA.TO.Check RVX.TO's competition here
MDNA.TO vs ONCO.CN Comparison April 2026
MDNA.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDNA.TO stands at 44M. In comparison, ONCO.CN has a market cap of 26M. Regarding current trading prices, MDNA.TO is priced at CA$0.64, while ONCO.CN trades at CA$0.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDNA.TO currently has a P/E ratio of -4.27, whereas ONCO.CN's P/E ratio is -60.00. In terms of profitability, MDNA.TO's ROE is -1.04%, compared to ONCO.CN's ROE of -2.29%. Regarding short-term risk, MDNA.TO is less volatile compared to ONCO.CN. This indicates potentially lower risk in terms of short-term price fluctuations for MDNA.TO.Check ONCO.CN's competition here
MDNA.TO vs AEZS.TO Comparison April 2026
MDNA.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDNA.TO stands at 44M. In comparison, AEZS.TO has a market cap of 25.4M. Regarding current trading prices, MDNA.TO is priced at CA$0.64, while AEZS.TO trades at CA$8.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDNA.TO currently has a P/E ratio of -4.27, whereas AEZS.TO's P/E ratio is -2.61. In terms of profitability, MDNA.TO's ROE is -1.04%, compared to AEZS.TO's ROE of -0.13%. Regarding short-term risk, MDNA.TO is less volatile compared to AEZS.TO. This indicates potentially lower risk in terms of short-term price fluctuations for MDNA.TO.Check AEZS.TO's competition here
MDNA.TO vs TELI.CN Comparison April 2026
MDNA.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDNA.TO stands at 44M. In comparison, TELI.CN has a market cap of 21.8M. Regarding current trading prices, MDNA.TO is priced at CA$0.64, while TELI.CN trades at CA$0.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDNA.TO currently has a P/E ratio of -4.27, whereas TELI.CN's P/E ratio is -10.00. In terms of profitability, MDNA.TO's ROE is -1.04%, compared to TELI.CN's ROE of -1.13%. Regarding short-term risk, MDNA.TO is less volatile compared to TELI.CN. This indicates potentially lower risk in terms of short-term price fluctuations for MDNA.TO.Check TELI.CN's competition here
MDNA.TO vs REUN.TO Comparison April 2026
MDNA.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDNA.TO stands at 44M. In comparison, REUN.TO has a market cap of 16.6M. Regarding current trading prices, MDNA.TO is priced at CA$0.64, while REUN.TO trades at CA$1.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDNA.TO currently has a P/E ratio of -4.27, whereas REUN.TO's P/E ratio is -0.43. In terms of profitability, MDNA.TO's ROE is -1.04%, compared to REUN.TO's ROE of -1.10%. Regarding short-term risk, MDNA.TO is more volatile compared to REUN.TO. This indicates potentially higher risk in terms of short-term price fluctuations for MDNA.TO.Check REUN.TO's competition here
MDNA.TO vs BLAB.CN Comparison April 2026
MDNA.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDNA.TO stands at 44M. In comparison, BLAB.CN has a market cap of 14.6M. Regarding current trading prices, MDNA.TO is priced at CA$0.64, while BLAB.CN trades at CA$0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDNA.TO currently has a P/E ratio of -4.27, whereas BLAB.CN's P/E ratio is 1.50. In terms of profitability, MDNA.TO's ROE is -1.04%, compared to BLAB.CN's ROE of +2.40%. Regarding short-term risk, MDNA.TO is more volatile compared to BLAB.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MDNA.TO.Check BLAB.CN's competition here
MDNA.TO vs DOSE.CN Comparison April 2026
MDNA.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDNA.TO stands at 44M. In comparison, DOSE.CN has a market cap of 14.5M. Regarding current trading prices, MDNA.TO is priced at CA$0.64, while DOSE.CN trades at CA$0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDNA.TO currently has a P/E ratio of -4.27, whereas DOSE.CN's P/E ratio is -5.50. In terms of profitability, MDNA.TO's ROE is -1.04%, compared to DOSE.CN's ROE of +0.76%. Regarding short-term risk, MDNA.TO is less volatile compared to DOSE.CN. This indicates potentially lower risk in terms of short-term price fluctuations for MDNA.TO.Check DOSE.CN's competition here
MDNA.TO vs IMV.TO Comparison April 2026
MDNA.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDNA.TO stands at 44M. In comparison, IMV.TO has a market cap of 13.1M. Regarding current trading prices, MDNA.TO is priced at CA$0.64, while IMV.TO trades at CA$1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDNA.TO currently has a P/E ratio of -4.27, whereas IMV.TO's P/E ratio is -0.18. In terms of profitability, MDNA.TO's ROE is -1.04%, compared to IMV.TO's ROE of -4.95%. Regarding short-term risk, MDNA.TO is less volatile compared to IMV.TO. This indicates potentially lower risk in terms of short-term price fluctuations for MDNA.TO.Check IMV.TO's competition here
MDNA.TO vs PREV.CN Comparison April 2026
MDNA.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDNA.TO stands at 44M. In comparison, PREV.CN has a market cap of 11.7M. Regarding current trading prices, MDNA.TO is priced at CA$0.64, while PREV.CN trades at CA$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDNA.TO currently has a P/E ratio of -4.27, whereas PREV.CN's P/E ratio is -2.00. In terms of profitability, MDNA.TO's ROE is -1.04%, compared to PREV.CN's ROE of +0.43%. Regarding short-term risk, MDNA.TO is less volatile compared to PREV.CN. This indicates potentially lower risk in terms of short-term price fluctuations for MDNA.TO.Check PREV.CN's competition here
MDNA.TO vs BCT.TO Comparison April 2026
MDNA.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDNA.TO stands at 44M. In comparison, BCT.TO has a market cap of 10.9M. Regarding current trading prices, MDNA.TO is priced at CA$0.64, while BCT.TO trades at CA$5.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDNA.TO currently has a P/E ratio of -4.27, whereas BCT.TO's P/E ratio is -0.29. In terms of profitability, MDNA.TO's ROE is -1.04%, compared to BCT.TO's ROE of -2.06%. Regarding short-term risk, MDNA.TO is more volatile compared to BCT.TO. This indicates potentially higher risk in terms of short-term price fluctuations for MDNA.TO.Check BCT.TO's competition here
MDNA.TO vs MDMA.CN Comparison April 2026
MDNA.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDNA.TO stands at 44M. In comparison, MDMA.CN has a market cap of 10.9M. Regarding current trading prices, MDNA.TO is priced at CA$0.64, while MDMA.CN trades at CA$0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDNA.TO currently has a P/E ratio of -4.27, whereas MDMA.CN's P/E ratio is -5.00. In terms of profitability, MDNA.TO's ROE is -1.04%, compared to MDMA.CN's ROE of -0.79%. Regarding short-term risk, MDNA.TO is more volatile compared to MDMA.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MDNA.TO.Check MDMA.CN's competition here
MDNA.TO vs BETR.CN Comparison April 2026
MDNA.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDNA.TO stands at 44M. In comparison, BETR.CN has a market cap of 10.6M. Regarding current trading prices, MDNA.TO is priced at CA$0.64, while BETR.CN trades at CA$0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDNA.TO currently has a P/E ratio of -4.27, whereas BETR.CN's P/E ratio is -7.00. In terms of profitability, MDNA.TO's ROE is -1.04%, compared to BETR.CN's ROE of +0.19%. Regarding short-term risk, MDNA.TO is less volatile compared to BETR.CN. This indicates potentially lower risk in terms of short-term price fluctuations for MDNA.TO.Check BETR.CN's competition here
MDNA.TO vs TBP.TO Comparison April 2026
MDNA.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDNA.TO stands at 44M. In comparison, TBP.TO has a market cap of 10.6M. Regarding current trading prices, MDNA.TO is priced at CA$0.64, while TBP.TO trades at CA$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDNA.TO currently has a P/E ratio of -4.27, whereas TBP.TO's P/E ratio is -0.31. In terms of profitability, MDNA.TO's ROE is -1.04%, compared to TBP.TO's ROE of -4.68%. Regarding short-term risk, MDNA.TO is more volatile compared to TBP.TO. This indicates potentially higher risk in terms of short-term price fluctuations for MDNA.TO.Check TBP.TO's competition here
MDNA.TO vs GLOW.CN Comparison April 2026
MDNA.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDNA.TO stands at 44M. In comparison, GLOW.CN has a market cap of 10M. Regarding current trading prices, MDNA.TO is priced at CA$0.64, while GLOW.CN trades at CA$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDNA.TO currently has a P/E ratio of -4.27, whereas GLOW.CN's P/E ratio is -2.75. In terms of profitability, MDNA.TO's ROE is -1.04%, compared to GLOW.CN's ROE of -0.96%. Regarding short-term risk, MDNA.TO is more volatile compared to GLOW.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MDNA.TO.Check GLOW.CN's competition here
MDNA.TO vs MCUR.CN Comparison April 2026
MDNA.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDNA.TO stands at 44M. In comparison, MCUR.CN has a market cap of 7M. Regarding current trading prices, MDNA.TO is priced at CA$0.64, while MCUR.CN trades at CA$0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDNA.TO currently has a P/E ratio of -4.27, whereas MCUR.CN's P/E ratio is -0.75. In terms of profitability, MDNA.TO's ROE is -1.04%, compared to MCUR.CN's ROE of -1.61%. Regarding short-term risk, MDNA.TO is more volatile compared to MCUR.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MDNA.TO.Check MCUR.CN's competition here
MDNA.TO vs COOL.CN Comparison April 2026
MDNA.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDNA.TO stands at 44M. In comparison, COOL.CN has a market cap of 6.8M. Regarding current trading prices, MDNA.TO is priced at CA$0.64, while COOL.CN trades at CA$0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDNA.TO currently has a P/E ratio of -4.27, whereas COOL.CN's P/E ratio is -1.32. In terms of profitability, MDNA.TO's ROE is -1.04%, compared to COOL.CN's ROE of -2.90%. Regarding short-term risk, MDNA.TO is more volatile compared to COOL.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MDNA.TO.Check COOL.CN's competition here
MDNA.TO vs PHRM.CN Comparison April 2026
MDNA.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDNA.TO stands at 44M. In comparison, PHRM.CN has a market cap of 6.4M. Regarding current trading prices, MDNA.TO is priced at CA$0.64, while PHRM.CN trades at CA$0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDNA.TO currently has a P/E ratio of -4.27, whereas PHRM.CN's P/E ratio is -3.50. In terms of profitability, MDNA.TO's ROE is -1.04%, compared to PHRM.CN's ROE of -1.67%. Regarding short-term risk, MDNA.TO is more volatile compared to PHRM.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MDNA.TO.Check PHRM.CN's competition here
MDNA.TO vs APS.TO Comparison April 2026
MDNA.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDNA.TO stands at 44M. In comparison, APS.TO has a market cap of 5.9M. Regarding current trading prices, MDNA.TO is priced at CA$0.64, while APS.TO trades at CA$2.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDNA.TO currently has a P/E ratio of -4.27, whereas APS.TO's P/E ratio is 2.43. In terms of profitability, MDNA.TO's ROE is -1.04%, compared to APS.TO's ROE of +1.69%. Regarding short-term risk, MDNA.TO is less volatile compared to APS.TO. This indicates potentially lower risk in terms of short-term price fluctuations for MDNA.TO.Check APS.TO's competition here
MDNA.TO vs TRYP.CN Comparison April 2026
MDNA.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDNA.TO stands at 44M. In comparison, TRYP.CN has a market cap of 5.8M. Regarding current trading prices, MDNA.TO is priced at CA$0.64, while TRYP.CN trades at CA$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDNA.TO currently has a P/E ratio of -4.27, whereas TRYP.CN's P/E ratio is -1.50. In terms of profitability, MDNA.TO's ROE is -1.04%, compared to TRYP.CN's ROE of +4.03%. Regarding short-term risk, MDNA.TO is more volatile compared to TRYP.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MDNA.TO.Check TRYP.CN's competition here
MDNA.TO vs CMND.CN Comparison April 2026
MDNA.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDNA.TO stands at 44M. In comparison, CMND.CN has a market cap of 5.1M. Regarding current trading prices, MDNA.TO is priced at CA$0.64, while CMND.CN trades at CA$1.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDNA.TO currently has a P/E ratio of -4.27, whereas CMND.CN's P/E ratio is -0.04. In terms of profitability, MDNA.TO's ROE is -1.04%, compared to CMND.CN's ROE of +44.20%. Regarding short-term risk, MDNA.TO is more volatile compared to CMND.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MDNA.TO.Check CMND.CN's competition here
MDNA.TO vs GTTX.CN Comparison April 2026
MDNA.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDNA.TO stands at 44M. In comparison, GTTX.CN has a market cap of 4.6M. Regarding current trading prices, MDNA.TO is priced at CA$0.64, while GTTX.CN trades at CA$0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDNA.TO currently has a P/E ratio of -4.27, whereas GTTX.CN's P/E ratio is -12.00. In terms of profitability, MDNA.TO's ROE is -1.04%, compared to GTTX.CN's ROE of -0.43%. Regarding short-term risk, MDNA.TO is more volatile compared to GTTX.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MDNA.TO.Check GTTX.CN's competition here
MDNA.TO vs GLAB.CN Comparison April 2026
MDNA.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDNA.TO stands at 44M. In comparison, GLAB.CN has a market cap of 4.6M. Regarding current trading prices, MDNA.TO is priced at CA$0.64, while GLAB.CN trades at CA$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDNA.TO currently has a P/E ratio of -4.27, whereas GLAB.CN's P/E ratio is -1.50. In terms of profitability, MDNA.TO's ROE is -1.04%, compared to GLAB.CN's ROE of +0.62%. Regarding short-term risk, MDNA.TO is more volatile compared to GLAB.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MDNA.TO.Check GLAB.CN's competition here
MDNA.TO vs AWKN.NE Comparison April 2026
MDNA.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDNA.TO stands at 44M. In comparison, AWKN.NE has a market cap of 3.9M. Regarding current trading prices, MDNA.TO is priced at CA$0.64, while AWKN.NE trades at CA$0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDNA.TO currently has a P/E ratio of -4.27, whereas AWKN.NE's P/E ratio is -0.36. In terms of profitability, MDNA.TO's ROE is -1.04%, compared to AWKN.NE's ROE of -4.29%. Regarding short-term risk, MDNA.TO is more volatile compared to AWKN.NE. This indicates potentially higher risk in terms of short-term price fluctuations for MDNA.TO.Check AWKN.NE's competition here
MDNA.TO vs CSCI.TO Comparison April 2026
MDNA.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDNA.TO stands at 44M. In comparison, CSCI.TO has a market cap of 3.9M. Regarding current trading prices, MDNA.TO is priced at CA$0.64, while CSCI.TO trades at CA$1.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDNA.TO currently has a P/E ratio of -4.27, whereas CSCI.TO's P/E ratio is -0.27. In terms of profitability, MDNA.TO's ROE is -1.04%, compared to CSCI.TO's ROE of -0.13%. Regarding short-term risk, MDNA.TO is less volatile compared to CSCI.TO. This indicates potentially lower risk in terms of short-term price fluctuations for MDNA.TO.Check CSCI.TO's competition here
MDNA.TO vs HEAL.CN Comparison April 2026
MDNA.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDNA.TO stands at 44M. In comparison, HEAL.CN has a market cap of 3.5M. Regarding current trading prices, MDNA.TO is priced at CA$0.64, while HEAL.CN trades at CA$0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDNA.TO currently has a P/E ratio of -4.27, whereas HEAL.CN's P/E ratio is -1.90. In terms of profitability, MDNA.TO's ROE is -1.04%, compared to HEAL.CN's ROE of +41.60%. Regarding short-term risk, MDNA.TO is more volatile compared to HEAL.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MDNA.TO.Check HEAL.CN's competition here
MDNA.TO vs ASEP.CN Comparison April 2026
MDNA.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDNA.TO stands at 44M. In comparison, ASEP.CN has a market cap of 3.4M. Regarding current trading prices, MDNA.TO is priced at CA$0.64, while ASEP.CN trades at CA$0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDNA.TO currently has a P/E ratio of -4.27, whereas ASEP.CN's P/E ratio is -0.32. In terms of profitability, MDNA.TO's ROE is -1.04%, compared to ASEP.CN's ROE of -0.59%. Regarding short-term risk, MDNA.TO is more volatile compared to ASEP.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MDNA.TO.Check ASEP.CN's competition here
MDNA.TO vs MYND.CN Comparison April 2026
MDNA.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDNA.TO stands at 44M. In comparison, MYND.CN has a market cap of 3.3M. Regarding current trading prices, MDNA.TO is priced at CA$0.64, while MYND.CN trades at CA$0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDNA.TO currently has a P/E ratio of -4.27, whereas MYND.CN's P/E ratio is -3.50. In terms of profitability, MDNA.TO's ROE is -1.04%, compared to MYND.CN's ROE of +0.36%. Regarding short-term risk, MDNA.TO is less volatile compared to MYND.CN. This indicates potentially lower risk in terms of short-term price fluctuations for MDNA.TO.Check MYND.CN's competition here
MDNA.TO vs IPCI.TO Comparison April 2026
MDNA.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDNA.TO stands at 44M. In comparison, IPCI.TO has a market cap of 2.6M. Regarding current trading prices, MDNA.TO is priced at CA$0.64, while IPCI.TO trades at CA$0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDNA.TO currently has a P/E ratio of -4.27, whereas IPCI.TO's P/E ratio is -0.67. In terms of profitability, MDNA.TO's ROE is -1.04%, compared to IPCI.TO's ROE of +0.31%. Regarding short-term risk, MDNA.TO is less volatile compared to IPCI.TO. This indicates potentially lower risk in terms of short-term price fluctuations for MDNA.TO.Check IPCI.TO's competition here
MDNA.TO vs MOOD.CN Comparison April 2026
MDNA.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDNA.TO stands at 44M. In comparison, MOOD.CN has a market cap of 2.5M. Regarding current trading prices, MDNA.TO is priced at CA$0.64, while MOOD.CN trades at CA$0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDNA.TO currently has a P/E ratio of -4.27, whereas MOOD.CN's P/E ratio is -3.93. In terms of profitability, MDNA.TO's ROE is -1.04%, compared to MOOD.CN's ROE of -0.63%. Regarding short-term risk, MDNA.TO is more volatile compared to MOOD.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MDNA.TO.Check MOOD.CN's competition here
MDNA.TO vs BIOV.CN Comparison April 2026
MDNA.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDNA.TO stands at 44M. In comparison, BIOV.CN has a market cap of 2.2M. Regarding current trading prices, MDNA.TO is priced at CA$0.64, while BIOV.CN trades at CA$0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDNA.TO currently has a P/E ratio of -4.27, whereas BIOV.CN's P/E ratio is -0.31. In terms of profitability, MDNA.TO's ROE is -1.04%, compared to BIOV.CN's ROE of +2.41%. Regarding short-term risk, MDNA.TO is less volatile compared to BIOV.CN. This indicates potentially lower risk in terms of short-term price fluctuations for MDNA.TO.Check BIOV.CN's competition here
MDNA.TO vs APLI.TO Comparison April 2026
MDNA.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDNA.TO stands at 44M. In comparison, APLI.TO has a market cap of 1.9M. Regarding current trading prices, MDNA.TO is priced at CA$0.64, while APLI.TO trades at CA$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDNA.TO currently has a P/E ratio of -4.27, whereas APLI.TO's P/E ratio is -0.75. In terms of profitability, MDNA.TO's ROE is -1.04%, compared to APLI.TO's ROE of +0.20%. Regarding short-term risk, MDNA.TO is more volatile compared to APLI.TO. This indicates potentially higher risk in terms of short-term price fluctuations for MDNA.TO.Check APLI.TO's competition here
MDNA.TO vs AGN.CN Comparison April 2026
MDNA.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDNA.TO stands at 44M. In comparison, AGN.CN has a market cap of 1.8M. Regarding current trading prices, MDNA.TO is priced at CA$0.64, while AGN.CN trades at CA$0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDNA.TO currently has a P/E ratio of -4.27, whereas AGN.CN's P/E ratio is -0.71. In terms of profitability, MDNA.TO's ROE is -1.04%, compared to AGN.CN's ROE of -0.93%. Regarding short-term risk, MDNA.TO is less volatile compared to AGN.CN. This indicates potentially lower risk in terms of short-term price fluctuations for MDNA.TO.Check AGN.CN's competition here
MDNA.TO vs BRAX.CN Comparison April 2026
MDNA.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDNA.TO stands at 44M. In comparison, BRAX.CN has a market cap of 1.4M. Regarding current trading prices, MDNA.TO is priced at CA$0.64, while BRAX.CN trades at CA$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDNA.TO currently has a P/E ratio of -4.27, whereas BRAX.CN's P/E ratio is -0.10. In terms of profitability, MDNA.TO's ROE is -1.04%, compared to BRAX.CN's ROE of -2.49%. Regarding short-term risk, MDNA.TO is more volatile compared to BRAX.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MDNA.TO.Check BRAX.CN's competition here
MDNA.TO vs ENBI.CN Comparison April 2026
MDNA.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDNA.TO stands at 44M. In comparison, ENBI.CN has a market cap of 1.4M. Regarding current trading prices, MDNA.TO is priced at CA$0.64, while ENBI.CN trades at CA$0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDNA.TO currently has a P/E ratio of -4.27, whereas ENBI.CN's P/E ratio is -3.33. In terms of profitability, MDNA.TO's ROE is -1.04%, compared to ENBI.CN's ROE of -0.79%. Regarding short-term risk, MDNA.TO is less volatile compared to ENBI.CN. This indicates potentially lower risk in terms of short-term price fluctuations for MDNA.TO.Check ENBI.CN's competition here
MDNA.TO vs HAVN.CN Comparison April 2026
MDNA.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDNA.TO stands at 44M. In comparison, HAVN.CN has a market cap of 1.2M. Regarding current trading prices, MDNA.TO is priced at CA$0.64, while HAVN.CN trades at CA$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDNA.TO currently has a P/E ratio of -4.27, whereas HAVN.CN's P/E ratio is -0.01. In terms of profitability, MDNA.TO's ROE is -1.04%, compared to HAVN.CN's ROE of -2.75%. Regarding short-term risk, MDNA.TO is more volatile compared to HAVN.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MDNA.TO.Check HAVN.CN's competition here
MDNA.TO vs CHGX.CN Comparison April 2026
MDNA.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDNA.TO stands at 44M. In comparison, CHGX.CN has a market cap of 415.6K. Regarding current trading prices, MDNA.TO is priced at CA$0.64, while CHGX.CN trades at CA$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDNA.TO currently has a P/E ratio of -4.27, whereas CHGX.CN's P/E ratio is -0.50. In terms of profitability, MDNA.TO's ROE is -1.04%, compared to CHGX.CN's ROE of +0.19%. Regarding short-term risk, MDNA.TO is more volatile compared to CHGX.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MDNA.TO.Check CHGX.CN's competition here
MDNA.TO vs CURE.CN Comparison April 2026
MDNA.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDNA.TO stands at 44M. In comparison, CURE.CN has a market cap of 408K. Regarding current trading prices, MDNA.TO is priced at CA$0.64, while CURE.CN trades at CA$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDNA.TO currently has a P/E ratio of -4.27, whereas CURE.CN's P/E ratio is 0.17. In terms of profitability, MDNA.TO's ROE is -1.04%, compared to CURE.CN's ROE of -0.17%. Regarding short-term risk, MDNA.TO is more volatile compared to CURE.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MDNA.TO.Check CURE.CN's competition here
MDNA.TO vs ABRT.CN Comparison April 2026
MDNA.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDNA.TO stands at 44M. In comparison, ABRT.CN has a market cap of 372.1K. Regarding current trading prices, MDNA.TO is priced at CA$0.64, while ABRT.CN trades at CA$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDNA.TO currently has a P/E ratio of -4.27, whereas ABRT.CN's P/E ratio is -0.10. In terms of profitability, MDNA.TO's ROE is -1.04%, compared to ABRT.CN's ROE of +16.27%. Regarding short-term risk, MDNA.TO is more volatile compared to ABRT.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MDNA.TO.Check ABRT.CN's competition here
MDNA.TO vs NIRV.CN Comparison April 2026
MDNA.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDNA.TO stands at 44M. In comparison, NIRV.CN has a market cap of 337.6K. Regarding current trading prices, MDNA.TO is priced at CA$0.64, while NIRV.CN trades at CA$0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDNA.TO currently has a P/E ratio of -4.27, whereas NIRV.CN's P/E ratio is 7.00. In terms of profitability, MDNA.TO's ROE is -1.04%, compared to NIRV.CN's ROE of +0.26%. Regarding short-term risk, MDNA.TO is more volatile compared to NIRV.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MDNA.TO.Check NIRV.CN's competition here
MDNA.TO vs WBIO.CN Comparison April 2026
MDNA.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDNA.TO stands at 44M. In comparison, WBIO.CN has a market cap of 324.8K. Regarding current trading prices, MDNA.TO is priced at CA$0.64, while WBIO.CN trades at CA$0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDNA.TO currently has a P/E ratio of -4.27, whereas WBIO.CN's P/E ratio is -3.50. In terms of profitability, MDNA.TO's ROE is -1.04%, compared to WBIO.CN's ROE of +0.15%. Regarding short-term risk, MDNA.TO is more volatile compared to WBIO.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MDNA.TO.Check WBIO.CN's competition here
MDNA.TO vs NSHS.CN Comparison April 2026
MDNA.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDNA.TO stands at 44M. In comparison, NSHS.CN has a market cap of 205.5K. Regarding current trading prices, MDNA.TO is priced at CA$0.64, while NSHS.CN trades at CA$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDNA.TO currently has a P/E ratio of -4.27, whereas NSHS.CN's P/E ratio is 0.50. In terms of profitability, MDNA.TO's ROE is -1.04%, compared to NSHS.CN's ROE of -0.22%. Regarding short-term risk, MDNA.TO is more volatile compared to NSHS.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MDNA.TO.Check NSHS.CN's competition here
MDNA.TO vs NOVA.CN Comparison April 2026
MDNA.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDNA.TO stands at 44M. In comparison, NOVA.CN has a market cap of 148.3K. Regarding current trading prices, MDNA.TO is priced at CA$0.64, while NOVA.CN trades at CA$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDNA.TO currently has a P/E ratio of -4.27, whereas NOVA.CN's P/E ratio is -0.05. In terms of profitability, MDNA.TO's ROE is -1.04%, compared to NOVA.CN's ROE of +3.18%. Regarding short-term risk, MDNA.TO is more volatile compared to NOVA.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MDNA.TO.Check NOVA.CN's competition here
MDNA.TO vs IN.TO Comparison April 2026
MDNA.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDNA.TO stands at 44M. In comparison, IN.TO has a market cap of 0. Regarding current trading prices, MDNA.TO is priced at CA$0.64, while IN.TO trades at CA$4.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDNA.TO currently has a P/E ratio of -4.27, whereas IN.TO's P/E ratio is -2.77. In terms of profitability, MDNA.TO's ROE is -1.04%, compared to IN.TO's ROE of -1.25%. Regarding short-term risk, MDNA.TO is less volatile compared to IN.TO. This indicates potentially lower risk in terms of short-term price fluctuations for MDNA.TO.Check IN.TO's competition here
MDNA.TO vs TRIL.TO Comparison April 2026
MDNA.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDNA.TO stands at 44M. In comparison, TRIL.TO has a market cap of 0. Regarding current trading prices, MDNA.TO is priced at CA$0.64, while TRIL.TO trades at CA$23.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDNA.TO currently has a P/E ratio of -4.27, whereas TRIL.TO's P/E ratio is -34.06. In terms of profitability, MDNA.TO's ROE is -1.04%, compared to TRIL.TO's ROE of -0.43%. Regarding short-term risk, MDNA.TO is more volatile compared to TRIL.TO. This indicates potentially higher risk in terms of short-term price fluctuations for MDNA.TO.Check TRIL.TO's competition here